NCIt definition : A FcR-enabled immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory
molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin
(Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with
potential immune checkpoint inhibitory activity. Upon administration, ralzapastotug
targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating
lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112
(nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor;
PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155
with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is
expressed on immune cells, such as natural killer (NK) cells and CD8 T-cells. This
leads to CD226 dimerization and CD226-mediated signaling and activates the immune
system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member
of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role
in the suppression of T-cell proliferation and activation; it is involved in tumor
cell immune evasion, and the inhibition of antiviral immune responses.;
UNII : J95TV367TU;
CAS number : 2581724-89-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2581724-89-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;